CN112638937B - 聚乙二醇化的破伤风神经毒素和张力减退的治疗 - Google Patents

聚乙二醇化的破伤风神经毒素和张力减退的治疗 Download PDF

Info

Publication number
CN112638937B
CN112638937B CN201980057158.3A CN201980057158A CN112638937B CN 112638937 B CN112638937 B CN 112638937B CN 201980057158 A CN201980057158 A CN 201980057158A CN 112638937 B CN112638937 B CN 112638937B
Authority
CN
China
Prior art keywords
ile
asn
leu
tent
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980057158.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638937A (zh
Inventor
T·麦克林
P·斯姆克
L·诺伯里
P·克洛伊
R·孔杜伊特
A·萨塞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Snoretox Ltd
Original Assignee
Snoretox Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902779A external-priority patent/AU2018902779A0/en
Application filed by Snoretox Ltd filed Critical Snoretox Ltd
Priority to CN202510841942.0A priority Critical patent/CN120661638A/zh
Publication of CN112638937A publication Critical patent/CN112638937A/zh
Application granted granted Critical
Publication of CN112638937B publication Critical patent/CN112638937B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
CN201980057158.3A 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗 Active CN112638937B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510841942.0A CN120661638A (zh) 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018902779 2018-07-31
AU2018902779A AU2018902779A0 (en) 2018-07-31 Composition and method
PCT/AU2019/050793 WO2020024002A1 (en) 2018-07-31 2019-07-30 Pegylated tetanus neurotoxins and treatment of hypotonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510841942.0A Division CN120661638A (zh) 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗

Publications (2)

Publication Number Publication Date
CN112638937A CN112638937A (zh) 2021-04-09
CN112638937B true CN112638937B (zh) 2025-06-17

Family

ID=69230503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980057158.3A Active CN112638937B (zh) 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗
CN202510841942.0A Pending CN120661638A (zh) 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510841942.0A Pending CN120661638A (zh) 2018-07-31 2019-07-30 聚乙二醇化的破伤风神经毒素和张力减退的治疗

Country Status (11)

Country Link
US (1) US12697379B2 (cg-RX-API-DMAC7.html)
EP (2) EP4134133A1 (cg-RX-API-DMAC7.html)
JP (3) JP2021533201A (cg-RX-API-DMAC7.html)
CN (2) CN112638937B (cg-RX-API-DMAC7.html)
AU (1) AU2019315327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021001520A2 (cg-RX-API-DMAC7.html)
CA (2) CA3108079C (cg-RX-API-DMAC7.html)
MX (1) MX2021001181A (cg-RX-API-DMAC7.html)
NZ (1) NZ772266A (cg-RX-API-DMAC7.html)
SG (1) SG11202100646SA (cg-RX-API-DMAC7.html)
WO (1) WO2020024002A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4417131A1 (en) 2023-02-15 2024-08-21 Canon Medical Systems Corporation X-ray diagnostic apparatus, x-ray diagnostic system, and x-ray diagnostic method

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118974A2 (en) * 2017-12-15 2019-06-20 The Medical College Of Wisconsin, Inc. Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
AU2003200441B2 (en) * 1998-04-29 2006-07-06 Allergan, Inc. Compositions and methods for modulating neural sprouting
GB9914861D0 (en) 1999-06-25 1999-08-25 Imperial College Tetanus toxin polypeptides
MXPA03000014A (es) 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
WO2003000193A2 (en) 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
US20040013687A1 (en) 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
WO2008024879A1 (en) * 2006-08-25 2008-02-28 University Of Maryland, Baltimore Use of tetanus toxin to amplify inadequate voluntary muscle contraction or to improve muscle tone in an animal actively vaccinated against the toxin and a regimen for treatment
WO2010124998A1 (en) * 2009-04-27 2010-11-04 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the amount of neurotoxin polypeptide and of its catalytic and proteolytic activities
WO2011115483A1 (en) 2010-03-15 2011-09-22 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Peptides, conjugates and method for increasing immunogenicity of a vaccine
EP3164149A1 (en) 2014-07-02 2017-05-10 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)
MX2018002183A (es) * 2015-08-27 2018-05-28 Harvard College Composiciones y metodos para tratamiento del dolor.
CN106692963B (zh) * 2016-12-28 2020-12-22 中国人民解放军军事医学科学院生物工程研究所 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗
WO2021155427A1 (en) * 2020-02-03 2021-08-12 Snoretox Pty Ltd Composition and method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019118974A2 (en) * 2017-12-15 2019-06-20 The Medical College Of Wisconsin, Inc. Modified clostridial neurotoxins as vaccines and conjugate vaccine platforms

Also Published As

Publication number Publication date
MX2021001181A (es) 2021-04-19
CA3108079A1 (en) 2020-02-06
EP3830110A4 (en) 2022-03-02
JP2021533201A (ja) 2021-12-02
CA3108079C (en) 2023-10-10
CA3167665A1 (en) 2020-02-06
WO2020024002A1 (en) 2020-02-06
CN120661638A (zh) 2025-09-19
NZ772266A (en) 2022-09-30
JP2026026159A (ja) 2026-02-16
EP3830110A1 (en) 2021-06-09
US12697379B2 (en) 2026-08-04
AU2019315327B2 (en) 2024-05-09
JP2024014975A (ja) 2024-02-01
AU2019315327A1 (en) 2021-02-11
CN112638937A (zh) 2021-04-09
US20210353724A1 (en) 2021-11-18
EP4134133A1 (en) 2023-02-15
BR112021001520A2 (pt) 2021-04-20
KR20210040407A (ko) 2021-04-13
SG11202100646SA (en) 2021-02-25
NZ789962A (en) 2025-07-25
JP7786745B2 (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
KR102550926B1 (ko) 이중 항체 구축물을 발현하는 aav를 포함하는 조성물 및 이들의 용도
CN111269925B (zh) 携带自杀基因的robo1 car-nk细胞及其制备方法和应用
CN113980991B (zh) 大肠杆菌-芽孢杆菌穿梭质粒载体及其构建方法和应用
KR20240032025A (ko) 내이의 세포 유형-특이적 유전자 발현을 위한 조성물 및 방법
CN112779292B (zh) 构建瘦肉率高、生长快且抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的方法及其应用
CN112725344B (zh) 密码子优化的smn1基因、腺相关病毒表达质粒及基因药物
KR102679920B1 (ko) 모노머형 스트렙타비딘을 발현하는 균주 및 비오틴화된 화합물을 포함하는 암 세포 표적용 조성물
CN111304141B (zh) 产n-乙酰-5-羟色胺的重组大肠杆菌及其构建方法和应用
CN112877362A (zh) 构建高繁殖力、抗蓝耳病和系列腹泻病的优质猪核移植供体细胞的基因编辑系统及其应用
CN112638937A (zh) 聚乙二醇化的破伤风神经毒素和张力减退的治疗
CN112522258A (zh) Il2rg基因和ada基因联合敲除的重组细胞及其在制备免疫缺陷猪模型中的应用
KR102679923B1 (ko) 모노머형 스트렙타비딘을 발현하기 위한 컨스트럭트
CN112680444B (zh) 用于oca2基因突变的crispr系统及其在构建白化病克隆猪核供体细胞中的应用
CN111500629B (zh) 一种高表达层粘连蛋白-511变体的方法及其应用
CN112342231A (zh) 一种不耐热ung融合蛋白的重组载体及表达纯化方法
CN109022487A (zh) 一种表达p65的基因载体及其用于治疗视网膜神经节细胞变性的基因治疗药物
CN112522309A (zh) 重症免疫缺陷猪源重组细胞及其制备方法和试剂盒
CN114107390B (zh) 一种用于表达抗体IgG1的rAAV载体及其应用
CN112522313B (zh) 用于构建TPH2基因突变的抑郁症克隆猪核供体细胞的CRISPR/Cas9系统
KR102774499B1 (ko) 예비표적화 단백질을 발현하는 균주를 포함하는 생체 내 미생물 추적 플랫폼
CN112813101B (zh) 一种构建瘦肉率高、生长快的优质猪核移植供体细胞的基因编辑系统及其应用
CN114958758B (zh) 一种乳腺癌模型猪的构建方法及应用
CN112795566A (zh) 用于构建骨质疏松症克隆猪核供体细胞系的opg基因编辑系统及其应用
CN112575033B (zh) Crispr系统及其在构建scn1a基因突变的癫痫性脑病克隆猪核供体细胞中的应用
CN112680453B (zh) Crispr系统及其在构建stxbp1突变的癫痫性脑病克隆猪核供体细胞中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20391115